News
December 16, 2024 News
Oblique Therapeutics – Business Update
Oblique Therapeutics presents at Redeye
December 9, 2024 News
Oblique Therapeutics announces an agreement with leading animal health company
Oblique Therapeutics has entered into an agreement with a leading animal health company to apply the AbiProt® technology to generate antibodies to a high-value target.
August 22, 2024 News
Oblique Therapeutics enters a research agreement with Eli Lilly and Company
Stockholm, Sweden - August 22, 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce that they have entered into a research collaboration agreement with Eli Lilly and Company (Lilly) to apply the AbiProt® technology to generate antibodies to a high-value target. This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties.
June 18, 2024 News
Oblique Therapeutics and KTH enters a strategic collaboration
Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers
January 15, 2024 News
Oblique Therapeutics presents at Redeye
Oblique Therapeutics presents at Redeye
November 28, 2023 News
Oblique Therapeutics forms strategic collaboration with AAX Biotech
November 17, 2023 News
Oblique Therapeutics enters an agreement with a large US-based pharmaceutical company
October 10, 2023 News
Oblique Therapeutics presents at the Redeye Neurology Theme Event
Event at Redeye, January 16 at Redeye – Stockholm
March 8, 2023 News
Report launch: The Swedish Drug Discovery and Development Pipeline 2023
SwedenBIO launches the long-awaited 2023 edition of the large, recurring mapping of the Swedish pharmaceutical pipeline.
February 8, 2023 News